company background image

Tilray Brands NasdaqGS:TLRY Stock Report

Last Price


Market Cap







04 Oct, 2022


Company Financials +
TLRY fundamental analysis
Snowflake Score
Future Growth1/6
Past Performance0/6
Financial Health4/6

TLRY Stock Overview

Tilray Brands, Inc. engages in the research, cultivation, production, marketing, and distribution of medical cannabis products in Canada, the United States, Europe, Australia, New Zealand, Latin America, and internationally.

Tilray Brands Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Tilray Brands
Historical stock prices
Current Share PriceUS$3.00
52 Week HighUS$13.95
52 Week LowUS$2.65
1 Month Change-10.71%
3 Month Change-14.29%
1 Year Change-72.97%
3 Year Changen/a
5 Year Changen/a
Change since IPO-81.37%

Recent News & Updates

Sep 29

Japan should permit medical cannabis, health ministry panel says

A health ministry panel in Japan recommended Thursday that the country allow the import, manufacture, and use of cannabis-derived medicines, applying the same approval process as pharmaceuticals. Announcing its findings in a report, the committee also said that Japan should do more to discourage the recreational use of cannabis. In Japan, cannabis passion is illegal but not its use, and the panel noted that only 1.4% of people in the country have ever tried marijuana, compared to 20-40% in the west. Citing cannabis-derived epilepsy drug Epidiolex, the committee noted that even if such treatments are approved in Japan, clinicians won’t be able to prescribe them due to limitations in the current Cannabis Control Act. Developed by Ireland-based Jazz Pharmaceuticals (JAZZ), Epidiolex has become the first CBD medication to undergo clinical trials in Japan for rare and severe forms of epilepsy. Meanwhile, on Wall Street, cannabis stocks opened higher on Thursday. Notable gainers included Columbia Care (OTCQX:CCHWF), Cresco Labs (OTCQX:CRLBF), TerrAscend (OTCQX:TRSSF), and Tilray (NASDAQ:TLRY)

Sep 21

Most Canadian cannabis LPs not following Aurora's decline after earnings disappointment

Although Aurora Cannabis (NASDAQ:ACB) reported fiscal 2022 Q4 earnings after Tuesday's closing that was seen as a disappointment to many leading to a share price decline, most other Canadian LPs are not following suit. Aurora is down 7% in early Wednesday afternoon trading. Cronos Group (NASDAQ:CRON) is higher by 1%, while Tilray Brands (NASDAQ:TLRY), Canopy Growth Corp. (NASDAQ:CGC), and Organigram Holdings (OGI) are all down by less than 1%. HEXO Corp. (HEXO) is down 3%. See why Seeking Alpha contributor Juxtaposed Ideas recently called Tilray (TLRY) a hold.

Shareholder Returns

TLRYUS PharmaceuticalsUS Market

Return vs Industry: TLRY underperformed the US Pharmaceuticals industry which returned 4.4% over the past year.

Return vs Market: TLRY underperformed the US Market which returned -20% over the past year.

Price Volatility

Is TLRY's price volatile compared to industry and market?
TLRY volatility
TLRY Average Weekly Movement13.2%
Pharmaceuticals Industry Average Movement11.3%
Market Average Movement6.9%
10% most volatile stocks in US Market15.5%
10% least volatile stocks in US Market2.8%

Stable Share Price: TLRY is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 13% a week.

Volatility Over Time: TLRY's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

n/a1,800Irwin Simon

Tilray Brands, Inc. engages in the research, cultivation, production, marketing, and distribution of medical cannabis products in Canada, the United States, Europe, Australia, New Zealand, Latin America, and internationally. The company operates through four segments: Cannabis Business, Distribution Business, Beverage Alcohol Business, and Wellness Business. It offers medical and adult-use cannabis products, including GMP-certified flowers, oils, vapes, edibles, and topicals; purchases and resells pharmaceutical and wellness products; and produces, markets, sells, and distributes beverage alcohol products, and hemp-based food and other wellness products.

Tilray Brands Fundamentals Summary

How do Tilray Brands's earnings and revenue compare to its market cap?
TLRY fundamental statistics
Market CapUS$1.88b
Earnings (TTM)-US$476.80m
Revenue (TTM)US$628.37m


P/S Ratio


P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
TLRY income statement (TTM)
Cost of RevenueUS$511.56m
Gross ProfitUS$116.82m
Other ExpensesUS$593.62m

Last Reported Earnings

May 31, 2022

Next Earnings Date

Oct 07, 2022

Earnings per share (EPS)-0.76
Gross Margin18.59%
Net Profit Margin-75.88%
Debt/Equity Ratio13.6%

How did TLRY perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.


Is TLRY undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score


Valuation Score 2/6

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for TLRY?

Other financial metrics that can be useful for relative valuation.

TLRY key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue3.4x
Enterprise Value/EBITDA-28.9x
PEG Ration/a

Price to Sales Ratio vs Peers

How does TLRY's PS Ratio compare to its peers?

TLRY PS Ratio vs Peers
The above table shows the PS ratio for TLRY vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPSEstimated GrowthMarket Cap
Peer Average5.2x
HRMY Harmony Biosciences Holdings
SUPN Supernus Pharmaceuticals
CORT Corcept Therapeutics
AMPH Amphastar Pharmaceuticals
TLRY Tilray Brands

Price-To-Sales vs Peers: TLRY is good value based on its Price-To-Sales Ratio (3x) compared to the peer average (5.2x).

Price to Earnings Ratio vs Industry

How does TLRY's PE Ratio compare vs other companies in the US Pharmaceuticals Industry?

Price-To-Sales vs Industry: TLRY is expensive based on its Price-To-Sales Ratio (3x) compared to the US Pharmaceuticals industry average (2.9x)

Price to Sales Ratio vs Fair Ratio

What is TLRY's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

TLRY PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio3x
Fair PS Ratio4.8x

Price-To-Sales vs Fair Ratio: TLRY is good value based on its Price-To-Sales Ratio (3x) compared to the estimated Fair Price-To-Sales Ratio (4.8x).

Share Price vs Fair Value

What is the Fair Price of TLRY when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate TLRY's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate TLRY's fair value for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

Future Growth

How is Tilray Brands forecast to perform in the next 1 to 3 years based on estimates from 17 analysts?

Future Growth Score


Future Growth Score 1/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings vs Savings Rate: TLRY is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: TLRY is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: TLRY is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: TLRY's revenue (12.1% per year) is forecast to grow faster than the US market (7.6% per year).

High Growth Revenue: TLRY's revenue (12.1% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: TLRY is forecast to be unprofitable in 3 years.

Discover growth companies

Past Performance

How has Tilray Brands performed over the past 5 years?

Past Performance Score


Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: TLRY is currently unprofitable.

Growing Profit Margin: TLRY is currently unprofitable.

Past Earnings Growth Analysis

Earnings Trend: TLRY is unprofitable, and losses have increased over the past 5 years at a rate of 62.4% per year.

Accelerating Growth: Unable to compare TLRY's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: TLRY is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (5%).

Return on Equity

High ROE: TLRY has a negative Return on Equity (-9.77%), as it is currently unprofitable.

Discover strong past performing companies

Financial Health

How is Tilray Brands's financial position?

Financial Health Score


Financial Health Score 4/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: TLRY's short term assets ($803.5M) exceed its short term liabilities ($280.3M).

Long Term Liabilities: TLRY's short term assets ($803.5M) exceed its long term liabilities ($728.0M).

Debt to Equity History and Analysis

Debt Level: TLRY's net debt to equity ratio (4.3%) is considered satisfactory.

Reducing Debt: TLRY's debt to equity ratio has increased from 12.2% to 13.6% over the past 5 years.

Balance Sheet

Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: TLRY has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if TLRY has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.

Discover healthy companies


What is Tilray Brands's current dividend yield, its reliability and sustainability?

Dividend Score


Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Cash Flow Coverage

Dividend Yield vs Market

Tilray Brands Dividend Yield vs Market
How does Tilray Brands dividend yield compare to the market?
SegmentDividend Yield
Company (Tilray Brands)n/a
Market Bottom 25% (US)1.6%
Market Top 25% (US)4.5%
Industry Average (Pharmaceuticals)2.6%
Analyst forecast in 3 Years (Tilray Brands)n/a

Notable Dividend: Unable to evaluate TLRY's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate TLRY's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if TLRY's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if TLRY's dividend payments have been increasing.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as TLRY has not reported any payouts.

Discover strong dividend paying companies


How experienced are the management team and are they aligned to shareholders interests?


Average management tenure


Irwin Simon (64 yo)





Mr. Irwin David Simon is Lead Independent Director at Stagwell Inc. and has been its Director since April 25, 2013. Mr. Simon previously served as a member of Board of Directors of MDC Partners Inc. since...

CEO Compensation Analysis

Irwin Simon's Compensation vs Tilray Brands Earnings
How has Irwin Simon's remuneration changed compared to Tilray Brands's earnings?
DateTotal Comp.SalaryCompany Earnings
May 31 2022n/an/a


Feb 28 2022n/an/a


Nov 30 2021n/an/a


Aug 31 2021n/an/a


May 31 2021US$14mUS$142k


Feb 28 2021n/an/a


Nov 30 2020n/an/a


Aug 31 2020n/an/a


May 31 2020US$13mUS$2m


Feb 29 2020n/an/a


Nov 30 2019n/an/a


Aug 31 2019n/an/a


May 31 2019US$7mUS$294k


Compensation vs Market: Irwin's total compensation ($USD13.68M) is above average for companies of similar size in the US market ($USD5.50M).

Compensation vs Earnings: Irwin's compensation has increased whilst the company is unprofitable.

Leadership Team

Experienced Management: TLRY's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.

Board Members

Experienced Board: TLRY's board of directors are considered experienced (3.5 years average tenure).


Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: TLRY insiders have only sold shares in the past 3 months.

Recent Insider Transactions

NasdaqGS:TLRY Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
09 Aug 22SellUS$46,800David HopkinsonIndividual12,000US$3.90

Ownership Breakdown

What is the ownership structure of TLRY?
Owner TypeNumber of SharesOwnership Percentage
Individual Insiders19,006,9273.1%
General Public522,761,46486.1%

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 31.6%.

Top Shareholders

Top 25 shareholders own 10.14% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
ETF Managers Group LLC
Morgan Stanley, Investment Banking and Brokerage Investments
8,274,919$24.8m220.28%no data
Brendan Kennedy
7,509,136$22.5m-8.53%no data
Susquehanna International Group, LLP, Asset Management Arm
Michael Blue
4,598,454$13.8m0%no data
Christian Groh
3,930,804$11.8m0%no data
Two Sigma Investments, LP
The Vanguard Group, Inc.
2,085,148$6.3m1.16%no data
Citadel Advisors LLC
BMO Asset Management Corp.
1,535,809$4.6m-6.93%no data
BlackRock, Inc.
1,429,168$4.3m2.38%no data
Sculptor Capital Management, Inc.
Public Sector Pension Investment Board
Swiss National Bank, Asset Management Arm
1,095,638$3.3m0%no data
Mirae Asset Global Investments Co., Ltd
1,082,600$3.2m-5.95%no data
AdvisorShares Investments, LLC
Irwin Simon
915,239$2.7m16.59%no data
TD Asset Management, Inc.
870,165$2.6m8.37%no data
Barclays PLC Private Banking & Investment Banking Investment
865,624$2.6m71.03%no data
California Public Employees' Retirement System
814,673$2.4m1.34%no data
Penserra Capital Management LLC
Geode Capital Management, LLC
736,983$2.2m16.78%no data
Thrivent Investment Management, Inc.
State Street Global Advisors, Inc.
686,392$2.1m6.51%no data
Michael B. Auerbach
655,153$2.0m0%no data

Company Information

Tilray Brands, Inc.'s employee growth, exchange listings and data sources

Key Information

  • Name: Tilray Brands, Inc.
  • Ticker: TLRY
  • Exchange: NasdaqGS
  • Founded: NaN
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: US$1.884b
  • Shares outstanding: 628.07m
  • Website:

Number of Employees


  • Tilray Brands, Inc.
  • 265 Talbot Street West
  • Leamington
  • Ontario
  • N8H 5L4
  • Canada


TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
TLRYTSX (The Toronto Stock Exchange)YesClass 2 Common SharesCACADJun 2019
TLRYNasdaqGS (Nasdaq Global Select)YesClass 2 Common SharesUSUSDJun 2019
2HQDB (Deutsche Boerse AG)YesClass 2 Common SharesDEEURJun 2019
2HQSWX (SIX Swiss Exchange)YesClass 2 Common SharesCHCHFJun 2019
2HQXTRA (XETRA Trading Platform)YesClass 2 Common SharesDEEURJun 2019
2HQBUL (Bulgaria Stock Exchange)YesClass 2 Common SharesBGEURJun 2019

Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/10/04 00:00
End of Day Share Price2022/10/04 00:00
Annual Earnings2022/05/31

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.